For research use only. Not for therapeutic Use.
Ruxolitinib phosphate (Cat No.:I008849) is a selective Janus kinase (JAK) inhibitor that has been approved for the treatment of myelofibrosis and polycythemia vera. By inhibiting JAK1 and JAK2, ruxolitinib phosphate suppresses the activity of the JAK-STAT signaling pathway, which plays a crucial role in the pathogenesis of these hematological malignancies. This results in a reduction in splenomegaly, alleviation of disease-related symptoms, and improvement in overall survival. Ruxolitinib phosphate has demonstrated efficacy in clinical trials and is considered a targeted therapy option for patients with myelofibrosis and polycythemia vera.
| Catalog Number | I008849 |
| CAS Number | 1092939-17-7 |
| Synonyms | ;(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate |
| Molecular Formula | C17H21N6O4P |
| Purity | ≥95% |
| Target | JAK |
| Solubility | Soluble in DMSO, not in water |
| Storage | Store at -20°C |
| Related CAS | 941678-49-5(free base) |
| IC50 | 3.3 nM/2.8 nM(JAK1/JAK2) |
| IUPAC Name | (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid |
| InChI | InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1 |
| InChIKey | JFMWPOCYMYGEDM-XFULWGLBSA-N |
| SMILES | C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O |
| Reference | <br /> |
